Compare IMMX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMMX | INMD |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 716.2M | 842.0M |
| IPO Year | 2021 | 2018 |
| Metric | IMMX | INMD |
|---|---|---|
| Price | $11.34 | $15.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $19.20 | $17.33 |
| AVG Volume (30 Days) | ★ 1.7M | 450.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.94 | $12.72 |
| 52 Week High | $12.14 | $16.74 |
| Indicator | IMMX | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.08 | 48.68 |
| Support Level | $7.96 | $14.94 |
| Resistance Level | $11.87 | $15.23 |
| Average True Range (ATR) | 0.73 | 0.24 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 88.99 | 16.67 |
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.